Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Lyell Immunopharma (LYEL) Leases (2020 - 2025)

Lyell Immunopharma's Leases history spans 6 years, with the latest figure at $19.9 million for Q3 2025.

  • For Q3 2025, Leases fell 45.69% year-over-year to $19.9 million; the TTM value through Sep 2025 reached $19.9 million, down 45.69%, while the annual FY2024 figure was $24.7 million, 37.63% down from the prior year.
  • Leases for Q3 2025 was $19.9 million at Lyell Immunopharma, down from $21.0 million in the prior quarter.
  • Across five years, Leases topped out at $48.4 million in Q2 2021 and bottomed at $19.9 million in Q3 2025.
  • The 5-year median for Leases is $41.1 million (2023), against an average of $38.1 million.
  • The largest annual shift saw Leases decreased 1.0% in 2021 before it tumbled 45.69% in 2025.
  • A 5-year view of Leases shows it stood at $46.5 million in 2021, then decreased by 7.09% to $43.2 million in 2022, then dropped by 8.28% to $39.7 million in 2023, then crashed by 37.63% to $24.7 million in 2024, then decreased by 19.51% to $19.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Leases are $19.9 million (Q3 2025), $21.0 million (Q2 2025), and $23.6 million (Q1 2025).